Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Evaluation of the Safety and Efficacy of Once-Daily Administrations of TZP 102 for the Treatment of Symptomatic Gastroparesis in Patients With Diabetes Mellitus
NCT00889486 is registered in ClinicalTrials.gov with Tranzyme, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Evaluation of the Safety and Efficacy of Once-Daily Administrations of TZP 102 for the Treatment of Symptomatic Gastroparesis in Patients With Diabetes Mellitus
- Lead sponsor
- Tranzyme, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 30, 2009
- Completion date
- April 30, 2010
- Enrollment
- 92 (actual)
- Sites
- 23
Conditions
As the registry lists them; a condition with its own page is linked.